Transforming promising drug candidates into life-changing medicines

After target validation, we pursue both biologics and small-molecule programs.

For biologics, we first select and prioritize therapeutically relevant target epitopes, then screen antibody repertoires to discover hit candidates with the desired binding, specificity, and functional properties. For small molecules, we combine computational design and experimental screening to identify compounds that effectively modulate the target or its associated pathways.

At the heart of our platform is a proprietary portfolio of patient-derived 2D and 3D tumor models, enabling us to optimize and validate therapeutic candidates in human tumor systems that closely reflect patient biology. The resulting data helps us select the strongest leads and make informed development decisions at an early stage. The most promising programs are then advanced toward key development milestones, either independently or together with pharmaceutical partners.

Throughout hit and lead development, we combine insights from our multi-omics and clinical database with experimental data from proprietary patient-derived tumor models established from the same patient samples used for target discovery. This unique continuity of patient biology links discovery directly to translational validation, generating clinically relevant data that support candidate selection and accelerate progression toward the clinic. Guided by a deep understanding of the target patient population, we inform patient selection and clinical trial design early to maximize the likelihood of clinical success.